ACE and myeloid sarcoma: Therefore, higher prevalence of MS vs. no MS patients were under ACE inhibitors [37 (37.4) vs. 19 (17.8), p-value 0.043], and ARS blockers [39 (39.4) vs. 23 (21.5), p-value 0.033].